首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1485292

運甲狀腺素蛋白澱粉樣變性治療市場 - 按類型、疾病類型、藥物類型、給藥途徑、配銷通路- 全球預測 2024 - 2032

Transthyretin Amyloidosis Treatment Market - By Type, Disease Type, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2024 - 2032

出版日期: 2024年03月13日 | 出版商:

Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在醫學研究和技術進步的推動下，轉甲狀腺素蛋白澱粉樣變性治療市場規模預計 2024 年至 2032 年間複合年成長率為 7.5%。最近，一些治療創新在阻止疾病進展和改善患者預後方面提供了有希望的結果。轉甲狀腺素蛋白澱粉樣變性的認知和診斷率不斷提高，特別是在人口老化地區，將有助於市場擴張。例如，全球範圍內發生的遺傳性轉甲狀腺素蛋白介導的 (hATTR) 可能會影響約 50,000 人，根據受影響的器官表現出不同的症狀。

此外，製藥公司和研究機構之間也開展了合作，透過利用綜合專業知識和資源來加速發現過程，從而促進新藥和療法的開發。越來越多的監管部門批准新療法以及轉甲狀腺素蛋白澱粉樣變性療法報銷範圍的擴大將進一步提高治療選擇的可及性。

轉甲狀腺素蛋白澱粉樣變性治療產業分為類型、疾病類型、藥物類型、給藥途徑、配銷通路、區域。

就給藥途徑而言，由於將治療劑直接輸送到血流中的功效和便利性，2024年至2032年期間腸胃外細分市場的市場規模預計將達到7.8%的複合年成長率。腸胃外方法確保藥物吸收快速且一致，避免了與口服給藥相關的胃腸道分解和變異性。對於經常出現胃腸道症狀和吸收不良問題的轉甲狀腺素蛋白澱粉樣變性患者來說，腸胃外給藥提供了有效遞送治療藥物的可靠方法。

根據配銷通路，到2032 年，線上藥局領域的轉甲狀腺素蛋白澱粉樣變性治療市場將錄得8% 的成長率。轉甲狀腺素蛋白澱粉樣變性的藥物他們的家。這種便利性對於居住在偏遠地區的患者和行動不便的患者特別有利，他們可能在進入傳統實體藥局時面臨挑戰。

到 2032 年，歐洲轉甲狀腺素蛋白澱粉樣變性治療市場規模將呈現 7.8% 的複合年成長率，這歸因於對醫療基礎設施和專注於罕見疾病的研究計劃的投資不斷增加。歐洲國家正在優先考慮醫療保健的進步，並分配大量資源來支持創新療法和治療方式。此外，監管機構還實施了加速核准途徑和激勵措施，以鼓勵孤兒藥的開發，進一步刺激了區域產業的擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 轉甲狀腺素蛋白澱粉樣變性病例盛行率增加
  - 新療法的開發
  - 老年人口不斷增加
  - 診斷技術的進步
- 產業陷阱與挑戰
  - 治療選擇有限
  - 治療費用高
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2018 - 2032

主要趨勢
ATTR 澱粉樣變性伴隨多發性神經病變 (ATTR-PN)
ATTR 澱粉樣變性伴隨心肌病變 (ATTR-CM)

第 6 章：市場估計與預測：按疾病類型，2018 - 2032

主要趨勢
遺傳性轉甲狀腺素蛋白澱粉樣變性
- 多發性神經病變
- 心肌病變
- 混合型
野生型轉甲狀腺素蛋白澱粉樣變性

第 7 章：市場估計與預測：按藥物類型，2018 - 2032

主要趨勢
塔法米迪斯
派蒂西蘭
伊諾特森
其他藥物類型

第 8 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

主要趨勢
口服
注射用

第 9 章：市場估計與預測：按配銷通路分類，2018 年 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥房

第 10 章：市場估計與預測：按地區，2018 - 2032

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 11 章：公司簡介

Acrotech Biopharma, LLC
Alnylam Pharmaceuticals, Inc.
AstraZeneca PLC
Astellas Pharma Inc.
BridgeBio Pharma, Inc.
Bristol-Myers Squibb Company
Ionis Pharmaceuticals, Inc.
Johnson & Johnson
Prothena Biosciences Limited
Pfizer Inc.
SOM Innovation Biotech, S.L.

簡介目錄

Product Code: 8484

Transthyretin amyloidosis treatment market size is expected to witness 7.5% CAGR between 2024 and 2032, driven by the advancements in medical research and technologies. Lately, several therapeutic innovations are offering promising outcomes in halting disease progression and improving patient outcomes. The increasing awareness and diagnosis rate of transthyretin amyloidosis, particularly in regions with aging population will contribute to the market expansion. For instance, the worldwide occurrence of hereditary transthyretin-mediated (hATTR) is likely to affect roughly 50,000 individuals, showcasing diverse symptoms depending on the organs affected.

Moreover, there have also been collaborations between pharmaceutical companies and research institutions to facilitate the development of new drugs and therapies by leveraging combined expertise and resources to accelerate the discovery process. Growing regulatory approvals for novel treatments and the expansion of reimbursement coverage for transthyretin amyloidosis therapies will further enhance the accessibility of treatment options.

The transthyretin amyloidosis treatment industry is divided into type, disease type, drug type, route of administration, distribution channel, and region.

With respect to route of administration, the market size from the parenteral segment is slated to depict 7.8% CAGR between 2024 to 2032, due to the efficacy and convenience in delivering therapeutic agents directly into the bloodstream. Parenteral method ensures rapid and consistent drug absorption, bypassing gastrointestinal degradation and variability associated with oral administration. For patients with transthyretin amyloidosis, who often experience gastrointestinal symptoms and malabsorption issues, parenteral administration offers a reliable means of delivering therapeutic agents effectively.

Based on distribution channel, the transthyretin amyloidosis treatment market from the online pharmacy segment will record 8% growth rate through 2032. These channels provide a convenient platform for individuals to purchase prescription medications and specialty treatments, including those for transthyretin amyloidosis, from the comfort of their homes. This accessibility is particularly beneficial for patients residing in remote areas and those with mobility limitations, who may face challenges accessing traditional brick-and-mortar pharmacies.

Europe transthyretin amyloidosis treatment market size will exhibit 7.8% CAGR through 2032, attributed to increasing investments in healthcare infrastructure and research initiatives focused on rare diseases. European countries are prioritizing healthcare advancements and allocating substantial resources to support innovative therapies and treatment modalities. Additionally, regulatory agencies have implemented expedited approval pathways and incentives to encourage the development of orphan drugs, further stimulating the regional industry expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of transthyretin amyloidosis cases
  - 3.2.1.2 Development of novel therapies
  - 3.2.1.3 Rising geriatric population
  - 3.2.1.4 Advancements in diagnostics techniques
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited treatment options
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 ATTR amyloidosis with polyneuropathy (ATTR-PN)
5.3 ATTR amyloidosis with cardiomyopathy (ATTR-CM)

Chapter 6 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Hereditary transthyretin amyloidosis
- 6.2.1 Polyneuropathy
- 6.2.2 Cardiomyopathy
- 6.2.3 Mixed type
6.3 Wild type transthyretin amyloidosis

Chapter 7 Market Estimates and Forecast, By Drug type, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Tafamidis
7.3 Patisiran
7.4 Inotersen
7.5 Other drug types

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacy
9.3 Retail drug stores
9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa